ChiCTR2300068346 版本V1.1 版本创建时间2023/08/10 22:07:19 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2300068346 

最近更新日期:

Date of Last Refreshed on:

2023-02-15 16:47:53 

注册时间:

Date of Registration:

2023-02-15 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

1 型糖尿病患儿葡萄糖目标范围内时间与糖尿病血管并发症的相关性研究

Public title:

Correlation between time in glucose target range and diabetic vascular complications in children with type 1 diabetes mellitus

注册题目简写:

English Acronym:

研究课题的正式科学名称:

1 型糖尿病患儿葡萄糖目标范围内时间与糖尿病血管并发症的相关性研究

Scientific title:

Correlation between time in glucose target range and diabetic vascular complications in children with type 1 diabetes mellitus

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

谌业净 

研究负责人:

吴利平 

Applicant:

Chen Yejing 

Study leader:

Wu Liping 

申请注册联系人电话:

Applicant telephone:

18875207959

研究负责人电话:

Study leader's
telephone:

13883994594

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

1176501767@qq.com

研究负责人电子邮件:

Study leader's E-mail:

lipingwu@cqmu.edu.cn

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

重庆市渝中区中山二路136号

研究负责人通讯地址:

重庆市渝中区中山二路136号

Applicant address:

No.136, Zhongshan 2nd Road, Yuzhong District, Chongqing

Study leader's address:

No.136, Zhongshan 2nd Road, Yuzhong District, Chongqing

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

重庆医科大学附属儿童医院

Applicant's institution:

Children's Hospital Affiliated to Chongqing Medical University

研究负责人所在单位:

重庆医科大学附属儿童医院

Affiliation of the Leader:

Children's Hospital Affiliated to Chongqing Medical University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

(2022)年伦审(研)第(545)号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

重庆医科大学附属儿童医院医学研究伦理委员会

Name of the ethic committee:

Review Approval of Ethics Committee of Children's Hospital Affiliated to Chongqing Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2023-01-10 00:00:00

伦理委员会联系人:

许红梅

Contact Name of the ethic committee:

Xu Hongmei

伦理委员会联系地址:

重庆市渝中区中山二路136号

Contact Address of the ethic committee:

No.136, Zhongshan 2nd Road, Yuzhong District, Chongqing

伦理委员会联系人电话:

Contact phone of the ethic committee:

023-63622754

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

重庆医科大学附属儿童医院

Primary sponsor:

Children's Hospital Affiliated to Chongqing Medical University

研究实施负责(组长)单位地址:

重庆市渝中区中山二路136号

Primary sponsor's address:

No.136, Zhongshan 2nd Road, Yuzhong District, Chongqing

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

重庆市

市(区县):

渝中区

Country:

China

Province:

Chongqing Municipality

City:

Yuzhong district

单位(医院):

重庆医科大学附属儿童医院

具体地址:

重庆市渝中区中山二路136号

Institution
hospital:

Children's Hospital Affiliated to Chongqing Medical University

Address:

No.136, Zhongshan Second Road, Yuzhong District, Chongqing

经费或物资来源:

重庆医科大学附属儿童医院

Source(s) of funding:

Children's Hospital Affiliated to Chongqing Medical University

研究疾病:

糖尿病  

Target disease:

Diabetes

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

横断面 

Study design:

Cross-sectional 

研究目的:

本研究拟通过CGM与SMBG同时计算T1DM患儿的TIR,比较两种方式所得TIR的一致性,筛选优化SMBG测量的时间方案,收集患儿TIR数据及血糖波动指标,分析SMBG优化方案所得TIR是否可用于糖尿病血管并发症早期预警  

Objectives of Study:

In this study, the TIR of T1DM children was calculated by CGM and SMBG at the same time, the consistency of TIR obtained by the two methods was compared, the time scheme of SMBG measurement was screened and optimized, the TIR data and blood glucose fluctuation indicators of T1DM children were collected, and whether TIR obtained by SMBG optimization scheme could be used for early warning of diabetic vascular complications was analyzed.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

纳入标准:(1)符合《中国 1 型糖尿病诊治指南(2020 版)》【中国儿童1型糖尿病标准化诊断与治疗专家共识(2020 版).中华儿科杂志,2020,58(6):447-454.】诊断标准的患者;(2)年龄<18岁;(3)知情同意参与本研究。

Inclusion criteria

Inclusion criteria: (1) in line with the "Guidelines for the Diagnosis and Treatment of Type 1 Diabetes in China (2020 Edition)" [Expert Consensus on Standardized Diagnosis and Treatment of Type 1 Diabetes in Children in China (2020 Edition). Chinese Journal of Pediatrics, 2020, 58 (6): 447-454.] Patients with diagnostic criteria; (2) age < 18 years; (3) informed consent to participate in the study.

排除标准:

(1)2型糖尿病或其他类型糖尿病的患者;(2)合并糖尿病急性并发症患者:糖尿病酮症酸中毒、乳酸酸中毒、高血糖高渗状态者及低血糖(反复低血糖、严重低血糖)等情况者;(3)合并有严重的心、肝、肾、免疫系统等疾病;(4)有严重的认知障碍或精神/心理疾病。

Exclusion criteria:

(1) Patients with type 2 diabetes mellitus or other types of diabetes mellitus; (2) Patients with acute complications of diabetes mellitus: diabetic ketoacidosis, lactic acidosis, hyperglycemic hyperosmolar state and hypoglycemia (repeated hypoglycemia, severe hypoglycemia); (3) Patients with severe heart, liver, kidney and immune system diseases; (4) Severe cognitive impairment or mental/psychological illness.

研究实施时间:

Study execute time:

From 2023-01-10 00:00:00 To 2025-07-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2023-02-15 00:00:00 To 2024-02-01 00:00:00

干预措施:

Interventions:

组别:

HbA1c≥7.5%组

样本量:

33

Group:

HbA1c≥7.5%group

Sample size:

干预措施:

安装CGM测量仪器,并监测SMBG

干预措施代码:

Intervention:

Install CGM measuring instrument and monitor SMBG.

Intervention code:

组别:

HbA1c≤7.5%组

样本量:

33

Group:

HbA1c≤7.5%group

Sample size:

干预措施:

安装CGM测量仪器,并监测SMBG

干预措施代码:

Intervention:

Install CGM measuring instrument and monitor SMBG.

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

重庆市 

市(区县):

渝中区 

Country:

China

Province:

Chongqing Municipality

City:

Yuzhong district

单位(医院):

重庆医科大学附属儿童医院 

单位级别:

三级甲等 

Institution
hospital:

Children's Hospital Affiliated to Chongqing Medical University

Level of the institution:

Grade three a

国家:

中国

省(直辖市):

四川省 

市(区县):

 

Country:

China

Province:

Sichuan Province

City:

单位(医院):

成都市妇女儿童中心医院 

单位级别:

三级甲等 

Institution
hospital:

Chengdu Women and Children Central Hospital

Level of the institution:

Grade three a

国家:

中国

省(直辖市):

吉林省 

市(区县):

 

Country:

China

Province:

Jilin province

City:

单位(医院):

长春市儿童医院 

单位级别:

三级甲等 

Institution
hospital:

Changchun children's hospital

Level of the institution:

Grade three a

国家:

中国

省(直辖市):

湖北省 

市(区县):

 

Country:

China

Province:

Hubei province

City:

单位(医院):

华中科技大学同济医学院附属同济医院 

单位级别:

三级甲等 

Institution
hospital:

Tongji hospital affiliated to Tongji Medical College, Huazhong University of Science and Technology

Level of the institution:

Grade three a

国家:

中国

省(直辖市):

云南省 

市(区县):

 

Country:

China

Province:

Yunnan province

City:

单位(医院):

昆明市儿童医院 

单位级别:

三级甲等 

Institution
hospital:

Kunming Children's Hospital

Level of the institution:

Grade three a

国家:

中国

省(直辖市):

浙江省 

市(区县):

 

Country:

China

Province:

Zhejiang Province

City:

单位(医院):

浙江大学医学院附属儿童医院 

单位级别:

三级甲等 

Institution
hospital:

Children's Hospital Affiliated to Zhejiang University School of Medicine

Level of the institution:

Grade three a

国家:

中国

省(直辖市):

江苏省 

市(区县):

 

Country:

China

Province:

Jiangsu Province

City:

单位(医院):

南京儿童医院 

单位级别:

三级甲等 

Institution
hospital:

Nanjing Children's Hospital

Level of the institution:

Grade three a

测量指标:

Outcomes:

指标中文名:

持续葡萄糖监测血糖

指标类型:

主要指标

Outcome:

Continuous glucose monitoring blood sugar

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

自我血糖监测血糖

指标类型:

主要指标

Outcome:

Self-blood sugar monitoring blood sugar

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

手指末梢血

Sample Name:

blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 0 years
最大 Max age 18 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

无随机方法,研究对象根据糖化血红蛋白值分组

Randomization Procedure (please state who generates the random number sequence and by what method):

There was no random method, and the subjects were grouped according to glycosylated hemoglobin value.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

若需要原数据请联系本研究项目负责人吴利平,邮箱为lipingwu@cqmu.edu.cn

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

If you need the original data, please contact Wu Liping, the person in charge of this research project, whose email address is lipingwu@cqmu.edu.cn.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

本研究数据采集及管理有病历记录本完成

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

The data collection and management of this study is completed by medical record book.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2023-02-15 16:47:46